Cargando…

An increase in MYC copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens

MYC translocations, a hallmark of Burkitt lymphoma, occur in 5-15% of diffuse large B-cell lymphoma, and have a negative prognostic impact. Numerical aberrations of MYC have also been detected in these patients, but their incidence and prognostic role are still controversial. We analyzed the clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Schieppati, Francesca, Balzarini, Piera, Fisogni, Simona, Re, Alessandro, Pagani, Chiara, Bianchetti, Nicola, Micheli, Lorenzo, Passi, Angela, Ferrari, Samantha, Maifredi, Adriana, Bottelli, Chiara, Leopaldo, Rossella, Pellegrini, Vilma, Facchetti, Fabio, Rossi, Giuseppe, Tucci, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193495/
https://www.ncbi.nlm.nih.gov/pubmed/31399522
http://dx.doi.org/10.3324/haematol.2019.223891
_version_ 1783528207751839744
author Schieppati, Francesca
Balzarini, Piera
Fisogni, Simona
Re, Alessandro
Pagani, Chiara
Bianchetti, Nicola
Micheli, Lorenzo
Passi, Angela
Ferrari, Samantha
Maifredi, Adriana
Bottelli, Chiara
Leopaldo, Rossella
Pellegrini, Vilma
Facchetti, Fabio
Rossi, Giuseppe
Tucci, Alessandra
author_facet Schieppati, Francesca
Balzarini, Piera
Fisogni, Simona
Re, Alessandro
Pagani, Chiara
Bianchetti, Nicola
Micheli, Lorenzo
Passi, Angela
Ferrari, Samantha
Maifredi, Adriana
Bottelli, Chiara
Leopaldo, Rossella
Pellegrini, Vilma
Facchetti, Fabio
Rossi, Giuseppe
Tucci, Alessandra
author_sort Schieppati, Francesca
collection PubMed
description MYC translocations, a hallmark of Burkitt lymphoma, occur in 5-15% of diffuse large B-cell lymphoma, and have a negative prognostic impact. Numerical aberrations of MYC have also been detected in these patients, but their incidence and prognostic role are still controversial. We analyzed the clinical impact of MYC increased copy number on 385 patients with diffuse large B-cell lymphoma screened at diagnosis for MYC, BCL2, and BCL6 rearrangements. We enumerated the number of MYC copies, defining as amplified those cases with an uncountable number of extra-copies. The prevalence of MYC translocation, increased copy number and amplification was 8.8%, 15%, and 1%, respectively. Patients with 3 or 4 gene copies, accounting for more than 60% of patients with MYC copy number changes, had a more favorable outcome compared to patients with >4 copies or translocation of MYC, and were not influenced by the type of treatment received as first-line. Stratification according to the number of MYC extra-copies showed a negative correlation between an increasing number of copies and survival. Patients with >7 copies or the amplification of MYC had the poorest prognosis. Patients with >4 copies of MYC showed a similar, trending towards worse prognosis compared to patients with MYC translocation. The survival of patients with >4 copies, translocation or amplification of MYC seemed to be superior if intensive treatments were used. Our study underlines the importance of fluorescence in situ hybridization testing at diagnosis of diffuse large B-cell lymphoma to detect the rather frequent and clinically significant numerical aberrations of MYC.
format Online
Article
Text
id pubmed-7193495
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Ferrata Storti Foundation
record_format MEDLINE/PubMed
spelling pubmed-71934952020-05-11 An increase in MYC copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens Schieppati, Francesca Balzarini, Piera Fisogni, Simona Re, Alessandro Pagani, Chiara Bianchetti, Nicola Micheli, Lorenzo Passi, Angela Ferrari, Samantha Maifredi, Adriana Bottelli, Chiara Leopaldo, Rossella Pellegrini, Vilma Facchetti, Fabio Rossi, Giuseppe Tucci, Alessandra Haematologica Articles MYC translocations, a hallmark of Burkitt lymphoma, occur in 5-15% of diffuse large B-cell lymphoma, and have a negative prognostic impact. Numerical aberrations of MYC have also been detected in these patients, but their incidence and prognostic role are still controversial. We analyzed the clinical impact of MYC increased copy number on 385 patients with diffuse large B-cell lymphoma screened at diagnosis for MYC, BCL2, and BCL6 rearrangements. We enumerated the number of MYC copies, defining as amplified those cases with an uncountable number of extra-copies. The prevalence of MYC translocation, increased copy number and amplification was 8.8%, 15%, and 1%, respectively. Patients with 3 or 4 gene copies, accounting for more than 60% of patients with MYC copy number changes, had a more favorable outcome compared to patients with >4 copies or translocation of MYC, and were not influenced by the type of treatment received as first-line. Stratification according to the number of MYC extra-copies showed a negative correlation between an increasing number of copies and survival. Patients with >7 copies or the amplification of MYC had the poorest prognosis. Patients with >4 copies of MYC showed a similar, trending towards worse prognosis compared to patients with MYC translocation. The survival of patients with >4 copies, translocation or amplification of MYC seemed to be superior if intensive treatments were used. Our study underlines the importance of fluorescence in situ hybridization testing at diagnosis of diffuse large B-cell lymphoma to detect the rather frequent and clinically significant numerical aberrations of MYC. Ferrata Storti Foundation 2020-05 /pmc/articles/PMC7193495/ /pubmed/31399522 http://dx.doi.org/10.3324/haematol.2019.223891 Text en Copyright© 2020 Ferrata Storti Foundation Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.
spellingShingle Articles
Schieppati, Francesca
Balzarini, Piera
Fisogni, Simona
Re, Alessandro
Pagani, Chiara
Bianchetti, Nicola
Micheli, Lorenzo
Passi, Angela
Ferrari, Samantha
Maifredi, Adriana
Bottelli, Chiara
Leopaldo, Rossella
Pellegrini, Vilma
Facchetti, Fabio
Rossi, Giuseppe
Tucci, Alessandra
An increase in MYC copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens
title An increase in MYC copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens
title_full An increase in MYC copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens
title_fullStr An increase in MYC copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens
title_full_unstemmed An increase in MYC copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens
title_short An increase in MYC copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens
title_sort increase in myc copy number has a progressive negative prognostic impact in patients with diffuse large b-cell and high-grade lymphoma, who may benefit from intensified treatment regimens
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193495/
https://www.ncbi.nlm.nih.gov/pubmed/31399522
http://dx.doi.org/10.3324/haematol.2019.223891
work_keys_str_mv AT schieppatifrancesca anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT balzarinipiera anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT fisognisimona anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT realessandro anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT paganichiara anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT bianchettinicola anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT michelilorenzo anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT passiangela anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT ferrarisamantha anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT maifrediadriana anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT bottellichiara anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT leopaldorossella anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT pellegrinivilma anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT facchettifabio anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT rossigiuseppe anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT tuccialessandra anincreaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT schieppatifrancesca increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT balzarinipiera increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT fisognisimona increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT realessandro increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT paganichiara increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT bianchettinicola increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT michelilorenzo increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT passiangela increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT ferrarisamantha increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT maifrediadriana increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT bottellichiara increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT leopaldorossella increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT pellegrinivilma increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT facchettifabio increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT rossigiuseppe increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens
AT tuccialessandra increaseinmyccopynumberhasaprogressivenegativeprognosticimpactinpatientswithdiffuselargebcellandhighgradelymphomawhomaybenefitfromintensifiedtreatmentregimens